Eovist

Gadoxetate Disodium

Gadoxetic acid is a gadolinium-based MRI contrast agent. Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals.[1][3] See also Gadobenic acid Gadopentetic acid References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-col...

Since 50% of the excretion is by the liver - I would think this is the ideal contrast for any patient with renal compromise. I know there is currently a clinical trial for this. however as in all cases the science and the prelimiary data seems so promising that I think this needs to be considered for the renal impaired patients. There are many patients who need contrast who have renal failure. The fact that this cojntrast is already 1/4 dose regular contrast and you could use this 1/2 dose at 3T for renal impaired patients would for me be perfectly acceptable if this finds the small liver met or small brain met which could not be detected otherwise. Benefits vs risks are what we balance every day. I am happy to hear your comments on this.

Drug Index

Gadoxetic acid is a gadolinium-based MRI contrast agent. Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals.[1][3] See also Gadobenic acid Gadopentetic acid References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-col...

NDC Database

Eovist 181.43 mg/ml Intravenous Injection, Solution by Bayer Healthcare Pharmaceuticals Inc. ## Package Codes: 50419-320-05, 50419-320-15, 50419-320-75 ## Active Ingredients: Gadoxetate Disodium